# Deerfield Catalyst

> Deerfield Catalyst is a New York medical-device incubator formed in 2021 by Deerfield Management and the veteran Coridea team. It combines clinical problem-finding, engineering, rapid prototyping, preclinical and clinical evaluation, company formation, and staged financing so promising device concepts can be tested before they become expensive standalone businesses.

- **Founded:** 2021
- **Headquarters:** New York, United States
- **Founders:** Howard Levin (Founding CEO & CMO), Mark Gelfand (Founding CTO)
- **Team size:** Approximately 10-15; LinkedIn lists 2-10 employees and provided company data lists 15.
- **Products:** Venture incubation, Clinical needs assessment, Concept generation and rapid prototyping, Preclinical and clinical evaluation, Company formation and financing support
- **Notable:** Launched in 2021 with a stated plan to form roughly 10 companies over five years., Built on a Coridea team record associated with companies and technologies including Ardian, Evalve, Respicardia, CHF Solutions, Cibiem and Axon Therapies., The management team reported more than 200 issued U.S. patents and more than $1.4 billion returned to investors across prior companies as of 2021.

## Products & services

- **Venture incubation** — Builds early-stage medical-device projects into standalone, financeable companies.
- **Clinical needs assessment** — Evaluates unmet clinical problems and the practical care pathways surrounding them.
- **Concept generation and rapid prototyping** — Turns selected needs into device concepts and working prototypes for iterative testing.
- **Preclinical and clinical evaluation** — Produces early evidence intended to reduce technical and clinical uncertainty before later financing.
- **Company formation and financing support** — Uses staged seed work to determine whether a project is ready for Series A formation and investment.

## Achievements

- Launched in 2021 with a stated plan to form roughly 10 companies over five years.
- Built on a Coridea team record associated with companies and technologies including Ardian, Evalve, Respicardia, CHF Solutions, Cibiem and Axon Therapies.
- The management team reported more than 200 issued U.S. patents and more than $1.4 billion returned to investors across prior companies as of 2021.
- Established collaborations spanning pediatric care, women's health translation, early feasibility studies and surgical innovation.
- A Deerfield Catalyst development subsidiary, DFC-01, secured up to $20 million in Series A financing according to transaction counsel.

## Latest updates

- **2025-09** — The company's public team page listed Howard Levin, Mark Gelfand, Zoar Engelman, Adam Rosenwach and Maybelle Jordan in senior roles.
- **2025** — NYU Langone identified Howard Levin as a judge in its Surgical Innovation Program, continuing Deerfield Catalyst's connection to clinician-led device development.
- **2024** — NYU's surgical innovation publication described Deerfield Catalyst as a program partner supporting a catheter concept through market analysis, prototyping and early intellectual-property work.
- **2022-06** — CobiCure launched with Deerfield Management and Coridea as initial collaborators to develop devices for rare pediatric conditions, beginning with functional single ventricle disorder.
- **2022-05** — Clinical Accelerator announced a collaboration with Deerfield Catalyst around medtech development and clinical translation.

## Links

- Website: https://www.dfcatalyst.com
- LinkedIn: https://www.linkedin.com/company/deerfield-catalyst

---

Profile page: https://yespress.io/deerfield-catalyst
Published by YesPress — https://yespress.io
Last updated: 2026-08-16